Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

During a live event, Pedro C. Barata, MD, MSc, discussed the case of a patient with advanced clear cell renal cell carcinoma ...

Detailed price information for Springworks Therapeutics Inc (SWTX-Q) from The Globe and Mail including charting and trades.

Annalisa Jenkins, the former head of R&D at Merck Serono, is one of the people behind the investment fund.

with the German firm’s Merck Serono division licensing various technologies used to engineer T-cells to target cancers, including its RheoSwitch platform for controlling gene expression and ...

The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD ...

Underinvested, Under-Referred, and Underserved: Applying a Gender Equity Continuum Framework in Cancer Control Continuum Programs and Policies to Expand to Transgender and Nonbinary Populations The ...

Bionxt Solutions is preparing for a pilot clinical trial to test its sublingual formulation of cladribine to treat multiple ...

Leading life science executives, government officials, academic leaders, and investors gather for two day off-the-record networking and discussion forum BOSTON, MASSACHUSETTS / ACCESS Newswire / May 1 ...

DESTIN, Fla. — Despite new therapies and evolving research, lupus nephritis continues to present clinical and research challenges, according to a presenter at the Congress of Clinical ...

Patients stopping immunotherapy due to side effects still experienced long-term benefits, with survival extending beyond 7 years. Factors predicting longer survival after treatment discontinuation ...